NextVivo

NextVivo is pioneering the development of immune organoid technology for drug development. Their innovative platform leverages human cells to create 3D organoids that replicate various tissues, including immune organs. These organoids provide highly relevant models for drug testing and discovery. NextVivo’s organoids are derived from human cells, offering a more accurate representation of human biology. They retain key immune cell types and their functional interactions, providing a more comprehensive model for drug testing. NextVivo’s platform can be used to generate a variety of organoids, including liver, lung, and tumor models. Additionally, NextVivo developed a lymphoid organoid with the germinal center and key antibody producing steps intact. This is the first model of the human adaptive immune response in a dish. NextVivo's lymphoid platform aims to generate fully human therapeutic antibodies with improved safety and efficacy. Using the patient’s own immune cells and their tumor organoids, NextVivo is working to develop personalized cancer cell therapies by replicating the immune system's response to tumors.

Jobs: